The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation

Abstract Germline variants within BRCA1 or BRCA2 genes account for approximately 25% of familial aggregations of breast-ovarian cancers. Low or no expression of BRCA1 in breast and ovarian cancers is associated with a good clinical response to treatment with platinum therapies and PARP1 inhibitors....

Full description

Bibliographic Details
Main Authors: Agnieszka Strumidło, Sylwia Skiba, Rodney J. Scott, Jan Lubiński
Format: Article
Language:English
Published: BMC 2017-09-01
Series:Hereditary Cancer in Clinical Practice
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13053-017-0076-7